The FMS-like tyrosine kinase 3 (FLT3) gene is mutated in approximately one third of patients
with acute myeloid leukemia (AML), either by internal tandem duplications (FLT3-ITD), or by …

The therapeutic landscape is rapidly changing, with eight new drugs approved by the Food
and Drug Administration within the last 2 years, including midostaurin and gilteritinib for …

Acute myeloid leukemia (AML) is a complex disease characterized by genetic and clinical
heterogeneity and high mortality. After 40 years during which the standard of care for …

Acute myeloid leukemia (AML) presents therapeutic challenges in older adults because of
high-risk leukemia biology conferring chemoresistance, and poor functional status resulting …

Acute Myeloid Leukemia (AML) is an extremely heterogeneous group of hematological
neoplasms, for which allogeneic stem cell transplantation (HSCT) still represents the only …

Background: The association between dysregulated microRNAs (miRNAs) and acute
myeloid leukemia (AML) is well known. However, our understanding of the regulatory role of …

Patients with high-risk myeloid neoplasms, including myelodysplastic syndrome (MDS) and
acute myeloid leukemia (AML), are offered allogeneic hematopoietic cell transplantation …

Background FLT3 mutation is present in 25–30% of all acute myeloid leukemias (AML), and
it is associated with adverse outcome. FLT3 inhibitors have shown improved survival results …

急性髓系白血病（ AML） 是一种高度异质性的恶性血液肿瘤， 其中伴FLT3
基因突变患者复发率较高、 预后较差， 因此FLT3 成为AML 治疗的重要靶点。 近年来 …

The therapeutic paradigm for treatment of acute myeloid leukemia (AML) is rapidly changing
with the advent of a new generation of drugs targeting diverse aspects of leukemogenesis …